Breast Cancer & Quality of Life in Older Adults
As of August 1, 2025, the landscape of cancer treatment continues to evolve, with a growing emphasis on personalized care and minimizing harm. While advancements in oncology offer unprecedented hope, the specter of overtreatment looms large, particularly for vulnerable patient populations. Overtreatment, defined as the submission of medical interventions that offer little to no benefit while possibly causing meaningful harm, is a critical concern.It not only diminishes a patient’s quality of life but also represents a considerable waste of healthcare resources and contributes to environmental damage through increased medical waste. This issue is especially pertinent when considering adjuvant therapies for older adult patients diagnosed with estrogen receptor-positive (ER+), HER2-negative breast cancer. These individuals, often exceeding 70 years of age, constitute a significant portion of the breast cancer demographic, yet have historically been underrepresented in clinical trials, leading to a gap in evidence-based treatment guidelines tailored to their unique needs and physiological profiles.
Understanding Overtreatment in Breast Cancer
Overtreatment in breast cancer refers to the management of therapies that are unlikely to improve survival or quality of life, and may rather lead to adverse effects. This can manifest in several ways:
Needless Chemotherapy: Administering chemotherapy to patients with very low-risk disease where the potential for recurrence is minimal.
Over-treatment of Ductal Carcinoma In Situ (DCIS): treating DCIS, a non-invasive form of breast cancer, with aggressive therapies when less invasive approaches might suffice.
Prolonged or Unnecessary endocrine Therapy: Continuing endocrine therapy beyond established benefit periods or for patients with a very low risk of recurrence.
Aggressive Treatment for Very Elderly or Frail Patients: Applying treatment regimens designed for younger, fitter patients to older adults with significant comorbidities, leading to disproportionate toxicity.The consequences of overtreatment are multifaceted. Patients may experience debilitating side effects from chemotherapy or radiation, such as fatigue, nausea, neuropathy, and increased risk of infection, all of which can severely impact their daily functioning and overall well-being.Financially,overtreatment strains healthcare systems and can lead to substantial out-of-pocket costs for patients. Environmentally, the production, transportation, and disposal of cancer medications and associated medical supplies contribute to a significant carbon footprint.
The Unique Challenges for Older Adults with Breast Cancer
The population of older adults with breast cancer presents a distinct set of challenges that necessitate careful consideration to avoid overtreatment. As noted, individuals over the age of 70 represent approximately one-third of all breast cancer patients. Though, this demographic has been historically underrepresented in clinical trials. This exclusion is often due to concerns about comorbidities, potential for increased toxicity from treatments, and logistical difficulties in trial participation.
Comorbidities and Treatment tolerance
Older adults frequently have one or more chronic health conditions, such as cardiovascular disease, diabetes, kidney disease, or arthritis. These comorbidities can significantly influence their tolerance to cancer therapies. For instance, chemotherapy regimens that are well-tolerated by younger, healthier individuals might be poorly tolerated by older adults with compromised organ function, leading to severe side effects that outweigh any potential oncological benefit.
Frailty and Performance Status
Frailty, a state of increased vulnerability to stressors, is more common in older adults. It is indeed frequently enough assessed through measures of physical function, muscle strength, and energy levels. Patients with poor performance status or frailty are at a higher risk of treatment-related toxicity and may not be able to complete standard treatment protocols. Therefore, treatment decisions must be individualized based on a comprehensive geriatric assessment, which evaluates not just the cancer but also the patient’s overall health, functional status, and psychosocial well-being.
The ER+/HER2- Breast Cancer Subtype in Older Adults
Estrogen receptor-positive (ER+), HER2-negative breast cancer is the most common subtype, particularly in postmenopausal women.For these patients, endocrine therapy, such as tamoxifen or aromatase inhibitors, is a cornerstone of adjuvant treatment. While generally well-tolerated compared to chemotherapy, endocrine therapies can still cause significant side effects, including hot flashes, joint pain, bone loss, and an increased risk of cardiovascular events or blood clots. For older adults, especially those with pre-existing cardiovascular issues or osteoporosis, these side effects can be particularly burdensome and may lead to treatment discontinuation.
The decision to add adjuvant chemotherapy to endocrine therapy for ER+/HER2- breast cancer in older adults requires a careful risk-benefit analysis. Genomic assays, such as Oncotype DX or MammaPrint, can help identify patients with a low risk of recurrence who are unlikely to benefit from chemotherapy. However, the interpretation and application of these tests in the very elderly population require further validation and consideration of individual patient factors.